宫颈癌是全球巨大的健康负担，尤其影响贫困国家的妇女。传统的治疗方法，如手术、放射治疗和化疗，经常导致全身毒性和无效。近年来，纳米医学已成为一种可行的策略，可以将治疗药物靶向递送至癌细胞，同时减少脱靶效应并提高治疗成功率。宫颈癌纳米医学引入了几个不同于以往治疗方案的新颖方面，例如定制的输送系统、精准靶向、联合治疗、实时监测和多样化的纳米载体以克服彼此的局限性。本摘要介绍了基于纳米医学的定制递送系统用于治疗宫颈癌的最新进展。脂质体、聚合物纳米颗粒、树枝状聚合物和碳纳米管都因其将化疗药物、核酸和显像剂转运至宫颈癌细胞的能力而受到深入研究。由于这些纳米载体的设计方式，它们可以跨越生物屏障并优先聚集在肿瘤部位，从而提高药物浓度并降低对健康组织的负面影响。用抗体、肽或适体等靶向配体对纳米载体进行表面修饰，通过识别肿瘤表面过度表达的受体或抗原来提高对癌细胞的特异性。此外，基于纳米医学的技术使得共同递送多种治疗药物成为可能，从而产生协同效应并克服耐药性。在临床前和临床研究中，化疗药物、基因治疗、免疫治疗和光动力治疗等联合治疗显示出令人鼓舞的结果，为个体化和多模式治疗方案开辟了新途径。此外，将造影剂和成像探针纳入纳米载体系统可以实现治疗反应的实时监测和成像。这使得能够评估治疗效果、早期诊断复发以及优化治疗方案。© 2023。作者获得 Springer Science Business Media, LLC（Springer Nature 旗下公司）的独家许可。

Cervical cancer is a huge worldwide health burden, impacting women in impoverished nations in particular. Traditional therapeutic approaches, such as surgery, radiation therapy, and chemotherapy, frequently result in systemic toxicity and ineffectiveness. Nanomedicine has emerged as a viable strategy for targeted delivery of therapeutic drugs to cancer cells while decreasing off-target effects and increasing treatment success in recent years. Nanomedicine for cervical cancer introduces several novel aspects that distinguish it from previous treatment options such as tailored delivery system, precision targeting, combination therapies, real-time monitoring and diverse nanocarriers to overcome the limitations of one another. This abstract presents recent advances in nanomedicine-based tailored delivery systems for the treatment of cervical cancer. Liposomes, polymeric nanoparticles, dendrimers, and carbon nanotubes have all been intensively studied for their ability to transport chemotherapeutic medicines, nucleic acids, and imaging agents to cervical cancer cells. Because of the way these nanocarriers are designed, they may cross biological barriers and preferentially aggregate at the tumor site, boosting medicine concentration and lowering negative effects on healthy tissues. Surface modification of nanocarriers with targeting ligands like antibodies, peptides, or aptamers improves specificity for cancer cells by identifying overexpressed receptors or antigens on the tumor surface. Furthermore, nanomedicine-based techniques have made it possible to co-deliver numerous therapeutic drugs, allowing for synergistic effects and overcoming drug resistance. In preclinical and clinical investigations, combination treatments comprising chemotherapeutic medicines, gene therapy, immunotherapy, and photodynamic therapy have showed encouraging results, opening up new avenues for individualized and multimodal treatment regimens. Furthermore, the inclusion of contrast agents and imaging probes into nanocarrier systems has enabled real-time monitoring and imaging of treatment response. This enables the assessment of therapy efficacy, the early diagnosis of recurrence, and the optimization of treatment regimens.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.